Haemonetics Corporation (HAE) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Medical - Instruments & Supplies
EV/EBITDA
↓
10.17
↓-54% vs avg
5yr avg: 22.11
30Y Low6.9·High50.5
P/FCF
↓
17.17
↓-59% vs avg
5yr avg: 41.76
30Y Low12.8·High114.9
P/B Ratio
↓
3.25
↓-37% vs avg
5yr avg: 5.16
30Y Low1.9·High8.8
ROE
↑
18.8%
↓+46% vs avg
5yr avg: 12.9%
30Y Low-12%·High19%
Debt/EBITDA
↓
3.70
↓-4% vs avg
5yr avg: 3.84
30Y Low0.0·High9.9
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
HAE Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Haemonetics Corporation trades at 15.9x earnings, 67% below its 5-year average of 48.0x, sitting at the 7th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.2x, the stock trades at a discount of 28%. On a free-cash-flow basis, the stock trades at 17.2x P/FCF, 59% below the 5-year average of 41.8x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.4B | $3.2B | $4.4B | $4.3B | $3.2B | $5.7B | $5.2B | $4.6B | $3.9B | $2.1B | $1.8B |
| Enterprise Value | $3.4B | $4.1B | $5.0B | $4.7B | $3.8B | $6.3B | $5.5B | $4.8B | $4.0B | $2.3B | $2.1B |
| P/E Ratio → | 15.90 | 19.09 | 37.27 | 36.94 | 75.26 | 71.62 | 67.34 | 84.12 | 86.07 | — | — |
| P/S Ratio | 1.80 | 2.36 | 3.35 | 3.64 | 3.27 | 6.54 | 5.22 | 4.79 | 4.33 | 2.36 | 1.96 |
| P/B Ratio | 3.25 | 3.91 | 4.57 | 5.20 | 4.33 | 7.78 | 8.80 | 6.93 | 5.20 | 2.83 | 2.47 |
| P/FCF | 17.17 | 22.50 | 38.00 | 26.13 | 42.86 | 79.34 | 47.18 | 114.87 | 26.89 | 25.00 | 91.51 |
| P/OCF | 13.46 | 17.64 | 24.14 | 15.58 | 18.85 | 52.33 | 32.64 | 29.08 | 17.76 | 13.09 | 14.61 |
P/E links to full P/E history page with 30-year chart
HAE EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Haemonetics Corporation's enterprise value stands at 10.2x EBITDA, 54% below its 5-year average of 22.1x. The Healthcare sector median is 14.1x, placing the stock at a 28% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.03 | 3.83 | 4.05 | 3.79 | 7.21 | 5.53 | 4.97 | 4.41 | 2.56 | 2.28 |
| EV / EBITDA | 10.17 | 12.47 | 19.79 | 19.67 | 22.52 | 36.08 | 27.97 | 24.94 | 27.42 | 35.04 | 50.49 |
| EV / EBIT | 15.17 | 16.69 | 24.25 | 28.33 | 35.83 | 62.74 | 32.99 | 57.60 | 62.15 | 57.77 | 47.43 |
| EV / FCF | — | 28.95 | 43.44 | 29.08 | 49.74 | 87.51 | 49.96 | 119.35 | 27.40 | 27.10 | 106.56 |
HAE Profitability
Margins and return-on-capital ratios measuring operating efficiency
Haemonetics Corporation earns an operating margin of 16.3%. Operating margins have expanded from 13.4% to 16.3% over the past 3 years, signaling improving operational efficiency. ROE of 18.8% indicates solid capital efficiency. ROIC of 10.0% represents adequate returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 57.2% | 57.2% | 54.4% | 53.3% | 53.4% | 49.2% | 49.4% | 43.2% | 45.6% | 42.7% | 44.7% |
| Operating Margin | 16.3% | 16.3% | 12.6% | 13.4% | 8.1% | 10.3% | 10.5% | 8.6% | 6.2% | -2.2% | -4.8% |
| Net Profit Margin | 12.3% | 12.3% | 9.0% | 9.9% | 4.4% | 9.1% | 7.7% | 5.7% | 5.0% | -3.0% | -6.1% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 18.8% | 18.8% | 13.2% | 14.7% | 5.9% | 12.1% | 12.2% | 7.7% | 6.1% | -3.6% | -7.2% |
| ROA | 7.2% | 7.2% | 5.7% | 6.1% | 2.4% | 5.1% | 6.0% | 4.4% | 3.7% | -2.1% | -4.0% |
| ROIC | 10.0% | 10.0% | 8.6% | 9.1% | 4.7% | 6.1% | 8.9% | 7.5% | 4.8% | -1.5% | -3.1% |
| ROCE | 11.8% | 11.8% | 9.2% | 10.1% | 5.4% | 7.0% | 10.2% | 8.8% | 6.0% | -1.8% | -3.6% |
HAE Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Haemonetics Corporation carries a Debt/EBITDA ratio of 3.7x, which is moderately leveraged (13% above the sector average of 3.3x). Net debt stands at $918M ($1.2B total debt minus $307M cash). Interest coverage of 25.4x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.49 | 1.49 | 0.84 | 0.94 | 1.04 | 1.06 | 0.75 | 0.52 | 0.34 | 0.43 | 0.57 |
| Debt / EBITDA | 3.70 | 3.70 | 3.19 | 3.18 | 4.67 | 4.47 | 2.26 | 1.81 | 1.74 | 4.87 | 9.93 |
| Net Debt / Equity | — | 1.12 | 0.66 | 0.59 | 0.70 | 0.80 | 0.52 | 0.27 | 0.10 | 0.24 | 0.41 |
| Net Debt / EBITDA | 2.78 | 2.78 | 2.48 | 2.00 | 3.12 | 3.37 | 1.56 | 0.94 | 0.51 | 2.71 | 7.13 |
| Debt / FCF | — | 6.44 | 5.45 | 2.96 | 6.88 | 8.17 | 2.78 | 4.48 | 0.51 | 2.09 | 15.05 |
| Interest Coverage | 25.35 | 25.35 | 15.89 | 11.43 | 6.14 | 5.95 | 10.23 | 8.43 | 14.18 | 4.84 | 4.62 |
HAE Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.62x means Haemonetics Corporation can comfortably meet its short-term obligations, though there is limited excess liquidity. The quick ratio of 0.99x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 3.06x to 1.62x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.62 | 1.62 | 2.56 | 3.06 | 1.71 | 2.74 | 2.20 | 2.44 | 1.35 | 2.42 | 2.64 |
| Quick Ratio | 0.99 | 0.99 | 1.50 | 2.03 | 1.05 | 1.46 | 1.21 | 1.62 | 0.94 | 1.58 | 1.63 |
| Cash Ratio | 0.53 | 0.53 | 0.60 | 1.13 | 0.59 | 0.76 | 0.50 | 0.72 | 0.47 | 0.66 | 0.62 |
| Asset Turnover | — | 0.56 | 0.60 | 0.60 | 0.53 | 0.48 | 0.78 | 0.76 | 0.73 | 0.72 | 0.69 |
| Inventory Turnover | 1.59 | 1.59 | 1.88 | 2.10 | 1.58 | 1.37 | 1.85 | 2.83 | 3.06 | 2.87 | 2.70 |
| Days Sales Outstanding | — | 54.36 | 57.60 | 55.95 | 58.57 | 53.49 | 61.00 | 69.80 | 61.06 | 62.89 | 63.09 |
HAE Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Haemonetics Corporation returns 9.2% to shareholders annually primarily through share buybacks. The earnings yield of 6.3% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 6.3% | 5.2% | 2.7% | 2.7% | 1.3% | 1.4% | 1.5% | 1.2% | 1.2% | — | — |
| FCF Yield | 5.8% | 4.4% | 2.6% | 3.8% | 2.3% | 1.3% | 2.1% | 0.9% | 3.7% | 4.0% | 1.1% |
| Buyback Yield | 9.2% | 7.0% | 0.0% | 1.8% | 0.0% | 0.0% | 3.4% | 3.5% | 2.6% | 0.0% | 3.4% |
| Total Shareholder Yield | 9.2% | 7.0% | 0.0% | 1.8% | 0.0% | 0.0% | 3.4% | 3.5% | 2.6% | 0.0% | 3.4% |
| Shares Outstanding | — | $51M | $51M | $51M | $51M | $51M | $52M | $53M | $54M | $52M | $51M |
Peer Comparison
Compare HAE with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 HAEYou | $2B | 15.9 | 10.2 | 17.2 | 57.2% | 16.3% | 18.8% | 10.0% | 3.7 |
 TFX | $5B | -6.1 | 18.0 | 22.2 | 56.2% | 12.8% | -24.5% | 3.4% | 6.3 |
 HOLX | $17B | 30.5 | 17.4 | 18.4 | 61.0% | 17.4% | 11.1% | 9.4% | 2.6 |
 ITGR | $3B | 29.9 | 13.0 | 28.2 | 23.1% | 11.3% | 6.1% | 5.4% | 4.2 |
 NVCR | $2B | -13.5 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 NNOX | $117M | -2.0 | — | — | -94.0% | -502.9% | -27.8% | -27.9% | — |
 BAX | $9B | -9.7 | 25.0 | 27.1 | 30.1% | -2.7% | -14.6% | -1.4% | 14.9 |
 BDX | $52B | 24.8 | 14.0 | 19.6 | 45.4% | 11.8% | 6.5% | 4.3% | 3.8 |
 ISRG | $160B | 57.4 | 43.4 | 64.4 | 66.0% | 29.3% | 16.6% | 15.0% | 0.1 |
 GMED | $12B | 22.8 | 19.4 | 20.5 | 67.4% | 16.3% | 12.3% | 8.9% | 0.2 |
 ATRC | $1B | -116.7 | 78.4 | 29.4 | 74.4% | -0.6% | -2.4% | -0.6% | 5.2 |
| Healthcare Median | — | 22.2 | 14.1 | 18.6 | 63.9% | -5.5% | -33.8% | -11.0% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
See HAE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs HAE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare HAE vs TFX
Side-by-side business, growth, and profitability comparison vs Teleflex Incorporated.
Start ComparisonHAE — Frequently Asked Questions
Quick answers to the most common questions about buying HAE stock.
What is Haemonetics Corporation's P/E ratio?
Haemonetics Corporation's current P/E ratio is 15.9x. The historical average is 44.6x. This places it at the 7th percentile of its historical range.
What is Haemonetics Corporation's EV/EBITDA?
Haemonetics Corporation's current EV/EBITDA is 10.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 17.4x.
What is Haemonetics Corporation's ROE?
Haemonetics Corporation's return on equity (ROE) is 18.8%. The historical average is 8.9%.
Is HAE stock overvalued?
Based on historical data, Haemonetics Corporation is trading at a P/E of 15.9x. This is at the 7th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Haemonetics Corporation's profit margins?
Haemonetics Corporation has 57.2% gross margin and 16.3% operating margin. Operating margin between 10-20% is typical for established companies.
How much debt does Haemonetics Corporation have?
Haemonetics Corporation's Debt/EBITDA ratio is 3.7x, indicating high leverage. A ratio between 2-4x is manageable but warrants monitoring.